The 31 references in paper N. Vorobieva M., E. Panchenko P., Н. ВОРОБЬЕВА М., Е. ПАНЧЕНКО П. (2015) “ВОЗМОЖНОСТИ ДАБИГАТРАНА ЭТЕКСИЛАТА В ЛЕЧЕНИИ ВЕНОЗНЫХ ТРОМБОЭМБОЛИЧЕСКИХ ОСЛОЖНЕНИЙ // DABIGATRAN ETEXILATE FOR THE TREATMENT OF VENOUS THROMBOEMBOLIC COMPLICATIONS” / spz:neicon:aterotromboz:y:2015:i:2:p:17-31

1
Oger E. Incidence of venous thromboembolism: a community-based study in Western France. Thromb Haemost, 2000. 83: 657–660.
(check this in PDF content)
2
Spencer FA, Emery C, Lessard D et al. The Worcester Venous Thromboembolism study: a population-based study of the clinical epidemiology of venous thromboembolism. J Gen Intern Med, 2006. 21: 722–727.
(check this in PDF content)
3
Deitelzweig SB, Johnson BH, Lin J, Schulman KL. Prevalence of clinical venous thromboembolism in the USA: current trends and future projections. Am J Hematol, 2011. 86: 217–220.
(check this in PDF content)
4
Kearon C, Akl EA, Comerota AJ et al. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9thed.: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest, 2012. 141 (Suppl): e419S–e494S.
(check this in PDF content)
5
Российские клинические рекомендации по диагностике, лечению и профилактике венозных тромбоэмболических осложнений. Флебология, 2010. 4 (1): 4–37.
(check this in PDF content)
6
Ansell J, Hirsh J, Hylek E et al. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8thEdition). Chest, 2008. 133 (Suppl): 160S–198S.
(check this in PDF content)
7
Baetz BE, Spinler SA. Dabigatran etexilate: an oral direct thrombin inhibitor for prophylaxis and treatment of thromboembolic diseases. Pharmacotherapy, 2008. 28: 1354–1373.
(check this in PDF content)
8
Eriksson BI, Dahl OE, Rosencher N et al. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost, 2007. 5: 2178–2185.
(check this in PDF content)
9
Eriksson BI, Dahl OE, Rosencher N et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet, 2007. 370: 949–956.
(check this in PDF content)
10
Connolly SJ, Ezekowitz MD, Yusuf S et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med, 2009. 361: 1139–1151.
(check this in PDF content)
11
Graham DJ, Reichman ME, Wernecke M et al. Cardiovascular, Bleeding, and Mortality Risks in Elderly Medicare Patients Treated with Dabigatran or Warfarin for Non-Valvular Atrial Fibrillation. Circulation, published online October 30, 2014. DOI: 10.1161/CIRCULATIONAHA.114.012061.
(check this in PDF content)
12
Schulman S, Kearon C, Kakkar AK et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med, 2009. 361: 2342–2352.
(check this in PDF content)
13
Schulman S, Kearon C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost, 2005. 3: 692–694.
(check this in PDF content)
14
Schulman S, Kakkar AK, Goldhaber SZ et al. Treatment of Acute Venous Thromboembolism With Dabigatran or Warfarin and Pooled Analysis. Circulation, 2014. 129: 764–772.
(check this in PDF content)
15
Walenga JM, Adiguzel C. Drug and dietary interactions of the new and emerging oral anticoagulants. Int J Clin Pract, 2010. 64: 956–967.
(check this in PDF content)
16
Gross PL, Weitz JI. New antithrombotic drugs. Clin Pharmacol Ther, 2009. 86: 139–146.
(check this in PDF content)
17
Rose AJ, Ozonoff A, Henault LE, Hylek EM. Warfarin for atrial fibrillation in community-based practice. J Thromb Haemost, 2008. 6: 1647–1654.
(check this in PDF content)
18
Fiessinger JN, Huisman MV, Davidson BL et al. Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomized trial. JAMA, 2005. 293: 681–689.
(check this in PDF content)
19
Schulman S, Wahlander K, Lundstrom T et al. Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran. N Engl J Med, 2003. 349: 1713–1721.
(check this in PDF content)
20
Ezekowitz MD, Reilly PA, Nehmiz G et al. Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study). Am J Cardiol, 2007. 100: 1419–1426.
(check this in PDF content)
21
The EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med, 2010. 363: 2499–2510.
(check this in PDF content)
22
The EINSTEIN-PE Investigators. Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary Embolism. N Engl J Med, 2012. 366: 1287–1297.
(check this in PDF content)
23
Agnelli G, Buller HR, Cohen A et al. AMPLIFY Investigators. Oral Apixaban for the Treatment of Acute Venous Thromboembolism. N Engl J Med, 2013. 369: 799–808.
(check this in PDF content)
24
Hokusai-VTE Investigators. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med, 2013. 369: 1406–1415.
(check this in PDF content)
25
Schafer AI. Venous thrombosis as a chronic disease. N Engl J Med, 1999. 340: 955–956.
(check this in PDF content)
26
Prandoni P, Lensing AW, Cogo A et al. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med, 1996. 125: 1–7.
(check this in PDF content)
27
Agnelli G, Prandoni P, Santamaria MG et al. Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. N Engl J Med, 2001. 345: 165–169.
(check this in PDF content)
28
Agnelli G, Prandoni P, Becattini C et al. Extended oral anticoagulant therapy after a first episode of pulmonary embolism. Ann Intern Med, 2003. 139: 19–25.
(check this in PDF content)
29
Kearon C, Gent M, Hirsh J et al. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med, 1999. 340: 901–907.
(check this in PDF content)
30
Schulman S, Kearon C, Kakkar AK et al. for the REMEDY and the RE-SONATE Trails Investigators. Extended Use of Dabigatran, Warfarin, or Placebo in Venous Thromboembolism. N Engl J Med, 2013. 368: 709–718.
(check this in PDF content)
31
Agnelli G, Buller HR, Cohen A et al. for the AMPLIFYEXT Investigators. Apixaban for Extended Treatment of Venous Thromboembolism. N Engl J Med, 2013. 368: 699–708.
(check this in PDF content)